Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 11:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: rhPSMA-7.3 (18F) Clear all
Active, not recruiting Phase 4 Interventional

PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer

NCT06479187
View directory record Official record
Conditions
Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Interventions
18F-rhPSMA-7.3, PET/CT
Drug · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

An Investigational Scan (18F-rhPSMA-7.3 PET-mpMRI) for Targeted Prostate Biopsy Using TRUS-MR Fusion Technique

NCT06865768
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Transrectal Ultrasonography Guided Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

NCT07220720
View directory record Official record
Conditions
Prostate
Interventions
Flotufolastat F 18
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

NCT04186819
View directory record Official record
Conditions
Prostate Cancer
Interventions
rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan
Drug · Diagnostic Test
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2025 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Early Phase 1 Interventional

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

NCT07164027
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Biopsy of Prostate, Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

NCT06617481
View directory record Official record
Conditions
Prostate Cancer (Post Prostatectomy)
Interventions
18F-rhPSMA-7.3 (Posluma)
Drug
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 1, 2026, 11:03 PM EDT
Completed Phase 1 Interventional

An Investigational Scan (rh PSMA 7.3 PET/MRI) for the Detection of Recurrent Disease and Aid in Radiotherapy Planning in Biochemically Recurrent Prostate Cancer

NCT04978675
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Fluorine F 18 rhPSMA-7.3, Magnetic Resonance Imaging, Positron Emission Tomography
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Sep 1, 2026, 11:03 PM EDT
Not listed Phase 3 Interventional

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management

NCT05799248
View directory record Official record
Conditions
Prostate Cancer
Interventions
rhPSMA-7.3 (18F)
Drug
Lead sponsor
MidLantic Urology
Other
Eligibility
18 Years and older · Male only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bala-Cynwyd, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 1, 2026, 11:03 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy

NCT05678322
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging
Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

NCT07285057
View directory record Official record
Conditions
Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Interventions
rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

NCT05413850
View directory record Official record
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms, Prostatic Neoplasms, Prostatic Diseases
Interventions
Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
Drug · Diagnostic Test
Lead sponsor
Blue Earth Therapeutics Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Miami, Florida • Atlanta, Georgia • Omaha, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Not applicable Interventional

Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment

NCT07011342
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-rhPSMA-7.3
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years and older · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Early Phase 1 Interventional

An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial

NCT06813898
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Positron Emission Tomography
Procedure · Other · Drug
Lead sponsor
Northwestern University
Other
Eligibility
Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Not applicable Interventional

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer

NCT06389786
View directory record Official record
Conditions
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Interventions
Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan, Computed Tomography, Electronic Health Record Review, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 85 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Completed Phase 3 Interventional Results available

Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

NCT04186845
View directory record Official record
Conditions
Prostate Cancer
Interventions
rhPSMA-7.3 (18F) Injection, Positron emission tomography scan
Drug · Diagnostic Test
Lead sponsor
Blue Earth Diagnostics
Industry
Eligibility
18 Years and older · Male only
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 1, 2026, 11:03 PM EDT
Active, not recruiting Phase 1 Interventional

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer

NCT06105918
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Flotufolastat F-18, Lutetium Lu 177 PSMA-10.1, Positron Emission Tomography, Single Photon Emission Computed Tomography
Procedure · Radiation · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2025 · Synced Sep 1, 2026, 11:03 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

NCT05779943
View directory record Official record
Conditions
Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
Interventions
Furosemide, F18-rhPSMA-7.3, Positron Emission Tomography, Computed Tomography
Drug · Other · Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
4
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 26, 2025 · Synced Sep 1, 2026, 11:03 PM EDT
Active, not recruiting Not applicable Interventional

[18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer

NCT06580015
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Computed Tomography, Flotufolastat F-18 Gallium, Medical Device Usage and Evaluation, Positron Emission Tomography
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
21 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance

NCT05852041
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Decipher Prostate Cancer Test, Flotufolastat F-18 Gallium, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography, Radical Prostatectomy
Procedure · Genetic · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2035
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Recruiting Phase 2 Interventional

Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial

NCT07025369
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Laparoscopic Radical Prostatectomy with Robotics, Pelvic Lymphadenectomy, Positron Emission Tomography, Relugolix
Procedure · Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 1, 2026, 11:03 PM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 1, 2026, 11:03 PM EDT